

Design and Synthesis of coumarin-based amphoteric antimicrobials with the biofilm interference and immunoregulation effects

Qun Tang^{1,2#}, Haiyang Zhang^{1#}, Kasemsiri Chandarajoti^{3,4}, Zirui Jiao^{1,2}, Lianhua Nie^{1,5}, Sai Lv^{1,2}, Jiakun Zuo¹,
Wen Zhou^{1,2*}, Xiangan Han^{1*}

¹*Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 200241, Shanghai,
China*

²*Key laboratory of Veterinary Chemical Drugs and Pharmaceutics, Ministry of Agriculture and Rural
Affairs, Shanghai Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241,
China*

³*Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Prince of Songkla
University, Hat Yai, Songkhla 90112, Thailand.*

⁴*Drug Delivery System Excellence Center, Faculty of Pharmaceutical Sciences, Prince of Songkla
University, Hat-Yai, Songkhla 90112, Thailand.*

⁵*College of Engineering, Shanxi Agricultural University, Taigu 030801, China*

* These authors contributed equally to this work

* Correspondent. E-mail: zhouwen60@126.com

* Correspondent. E-mail: hanxgan@163.com

Table of Contents

General procedure for preparation of target compound.	1-2
Spectral data.	3-10
Spectral spectrum	11-41

General procedure for preparation of target compound 2

2 Properly substituted resorcinol (100 mmol) was dissolved in dioxane (100 ml) and ethylpropiolate (100 mmol), and dried zinc chloride (100 mmol) was added. The mixture was refluxed for 24 h. After cooling to room temperature, 100 ml of 5% HCl was added slowly. After addition, the mixture was concentrated to half volume and kept at 4°C. The precipitate was filtered and dried at room temperature. The product (**2**) was recrystallised from ethanol.

General procedure for preparation of target compound 10

To a stirred mixture of **9** (1.15 mmol) and sodium hydride (138 mg, 5.75 mmol) in 5 ml dry toluene, a solution of the diethyl carbonate (1.15 mmol) in dry toluene was dropped. The mixture was reacted at 0°C for 30 min, then heated to reflux and reacted for another 4 h. The reaction mixture was quenched with water (20 mL) at ice bath and neutralized to pH 7 with 2 N HCl. The precipitate was filtered, washed with cold water and dried to get **10**.

General procedure for preparation of target compound 3-5 and 11-13

The appropriate dibromoalkane (1.5 mmol) was added to a solution of hydroxycoumarin (1.5 mmol) and potassium carbonate (3 mmol) in acetone (50 mL) with stirring. The mixture was heated at refluxed and the reaction was monitored by TLC. After cooling, the mixture was separated and the solvent was evaporated. The crude product was Purification by column chromatography to yield compounds **3-5** and **11-13**.

General procedure for preparation of target compound 6-8 and 14-16

The appropriate Amino group (1.5 mmol) was added to a solution of coumarin derivatives (1.5 mmol) and potassium carbonate (3 mmol) in acetone (50 mL) with stirring. The mixture was heated at refluxed and the

reaction was monitored by TLC. After cooling, the mixture was separated and the solvent was evaporated. The crude product was Purification by column chromatography to yield compounds **6-8** and **14-16**.

7-hydroxy-2H-chromen-2-one (2)

¹H NMR (400 MHz, DMSO-d6) δ = 10.54 (s, 1H), 7.91 (d, *J* = 9.5 Hz, 1H), 7.51 (d, *J* = 8.5 Hz, 1H), 6.78 (dd, *J* = 8.5, 2.3 Hz, 1H), 6.71 (d, *J* = 2.2 Hz, 1H), 6.19 (d, *J* = 9.5 Hz, 1H).

7-(4-bromobutoxy)-2H-chromen-2-one (3)

¹H NMR (400 MHz, DMSO) δ = 7.98 – 7.95 (d, *J* = 12 Hz, 1H), 7.61 – 7.59 (d, 1H), 6.96 – 6.91 (m, 2H), 6.28 – 6.25 (d, *J* = 12 Hz, 1H), 4.12 – 4.08 (t, *J* = 8 Hz, 2H), 3.62 – 3.59 (t, *J* = 6 Hz, 2H), 2.00 – 1.82 (m, 4H). ¹³C NMR (100 MHz, DMSO) δ = 161.63, 160.17, 155.31, 144.18, 129.36, 112.60, 112.34, 101.08, 67.36, 34.58, 28.90, 27.08. TOF-MS, m/z: [M+H⁺] calculated for C₁₃H₁₃BrO₃, 296.0048, found: 297.0148.

7-((8-bromoocetyl)oxy)-2H-chromen-2-one (4)

¹H NMR (400 MHz, DMSO) δ = 7.99 – 7.97 (d, *J* = 8 Hz, 1H), 7.62 – 7.60 (d, 1H), 6.96 – 6.91 (m, 2H), 6.28 – 6.26 (d, *J* = 8 Hz, 1H), 4.08 – 4.04 (t, *J* = 8 Hz, 2H), 3.53 – 3.50 (t, *J* = 6 Hz, 2H), 1.81 – 1.71 (m, 4H), 1.40 – 1.27 (m, 8H). ¹³C NMR (100 MHz, DMSO) δ = 161.83, 160.23, 155.37, 144.26, 129.39, 112.64, 112.30, 101.06, 68.22, 35.11, 32.16, 28.48, 28.33, 27.98, 27.89, 27.41, 27.37, 25.27. TOF-MS, m/z: [M+H⁺] calculated for C₁₇H₂₁BrO₃, 352.0674, found: 353.0975.

7-((12-bromododecyl)oxy)-2H-chromen-2-one (5)

¹H NMR (400 MHz, CDCl₃) δ = 7.63 – 7.60 (d, *J* = 6 Hz, 1H), 7.35 – 7.33 (d, 1H), 6.83 – 6.78 (m, 2H), 6.23 – 6.21 (d, *J* = 8 Hz, 1H), 4.01 – 3.98 (t, *J* = 8 Hz, 2H), 3.41 – 3.37 (t, *J* = 8 Hz, 2H), 1.87 – 1.76 (m, 4H), 1.47 – 1.28 (m, 16H). ¹³C NMR (100 MHz, DMSO) δ = 162.40, 161.18, 155.89, 144.18, 128.63, 112.93, 112.33, 101.32, 68.63, 33.93, 32.79, 29.44, 29.36, 29.25, 28.93, 28.70, 28.12, 25.89. TOF-MS, m/z: [M+H⁺] calculated for C₂₁H₂₉BrO₃, 408.1300, found: 409.1377.

7-(4-(dimethylamino)butoxy)-2H-chromen-2-one (6a)

¹H NMR (400 MHz, DMSO) δ 7.98 (d, *J* = 9.4 Hz, 1H), 7.61 (d, *J* = 8.6 Hz, 1H), 6.99

– 6.90 (m, 2H), 6.27 (dd, J = 9.5, 1.3 Hz, 1H), 4.08 (t, J = 6.5 Hz, 2H), 1.74 (p, J = 6.7 Hz, 2H), 1.57 (q, J = 7.6 Hz, 2H), 1.42 (d, J = 7.6 Hz, 2H), 0.83 (t, J = 7.3 Hz, 6H). ^{13}C NMR (101 MHz, DMSO) δ 162.28, 160.74, 155.87, 144.79, 129.92, 113.16, 112.83, 112.71, 101.57, 68.61, 26.66, 12.09.

7-(4-(diethylamino)butoxy)-2H-chromen-2-one (6b**)**

^1H NMR (400 MHz, DMSO) δ 8.00 (d, J = 9.5 Hz, 1H), 7.64 (d, J = 8.6 Hz, 1H), 7.06 – 6.90 (m, 2H), 6.29 (d, J = 9.5 Hz, 1H), 4.12 (d, J = 5.5 Hz, 2H), 3.10 (q, J = 6.9 Hz, 5H), 1.90 – 1.69 (m, 4H), 1.20 (t, J = 7.2 Hz, 5H). ^{13}C NMR (101 MHz, DMSO) δ 162.13, 160.73, 155.88, 144.80, 130.00, 113.19, 112.96, 112.86, 101.70, 68.15, 50.96, 46.81, 26.06, 20.65, 9.13.

7-(4-(dipropylamino)butoxy)-2H-chromen-2-one (6c**)**

^1H NMR (400 MHz, DMSO) δ 7.69 – 7.53 (m, 2H), 6.99 (d, J = 15.5 Hz, 1H), 6.50 – 6.39 (m, 2H), 3.96 (t, J = 5.7 Hz, 2H), 3.09 (d, J = 8.0 Hz, 4H), 2.90 (q, J = 6.3, 4.8 Hz, 3H), 2.76 (s, 5H), 2.53 (d, J = 1.1 Hz, 2H), 1.76 (dq, J = 13.1, 7.3, 6.7 Hz, 4H), 1.18 (t, J = 7.2 Hz, 1H). ^{13}C NMR (101 MHz, DMSO) δ 166.79, 160.98, 158.05, 136.92, 129.94, 115.60, 115.06, 106.58, 102.15, 67.16, 56.76, 42.62, 34.69, 26.13, 21.20.

7-(4-(dibutylamino)butoxy)-2H-chromen-2-one (6d**)**

^1H NMR (400 MHz, CDCl_3) δ 7.51 (t, J = 9.5 Hz, 1H), 7.25 – 7.19 (m, 1H), 6.75 – 6.58 (m, 2H), 6.13 – 6.02 (m, 1H), 3.91 (dt, J = 9.4, 6.2 Hz, 2H), 2.44 – 2.17 (m, 7H), 1.71 (ddt, J = 15.2, 8.8, 6.5 Hz, 2H), 1.49 (qd, J = 9.2, 8.8, 6.4 Hz, 3H), 1.36 – 1.24 (m, 4H), 1.23 – 1.00 (m, 7H), 0.79 (dt, J = 9.6, 7.3 Hz, 7H). ^{13}C NMR (101 MHz, CDCl_3) δ 162.25, 155.76, 143.32, 128.63, 112.71, 112.69, 112.67, 112.65, 112.25, 101.19, 68.41, 53.68, 53.57, 29.12, 26.88, 23.51, 20.58, 13.96.

7-((8-(dimethylamino)octyl)oxy)-2H-chromen-2-one (7a**)**

^1H NMR (400 MHz, DMSO) δ 7.99 (d, J = 9.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.04

– 6.85 (m, 2H), 6.27 (dd, J = 9.4, 1.0 Hz, 1H), 4.06 (t, J = 6.5 Hz, 2H), 2.97 (dd, J = 9.6, 6.6 Hz, 2H), 2.70 (d, J = 1.4 Hz, 4H), 1.77 – 1.55 (m, 3H), 1.47 – 1.19 (m, 7H). ^{13}C NMR (101 MHz, DMSO) δ 162.34, 160.77, 155.89, 144.82, 129.97, 113.17, 112.84, 112.72, 101.58, 68.75, 57.19, 42.75, 42.72, 28.93, 28.89, 28.84, 26.33, 25.78, 24.29.

7-((8-(diethylamino)octyl)oxy)-2H-chromen-2-one (7b)

^1H NMR (400 MHz, DMSO) δ 7.99 (d, J = 9.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.03 – 6.88 (m, 2H), 6.27 (d, J = 9.5 Hz, 1H), 4.06 (t, J = 6.5 Hz, 2H), 3.08 (q, J = 7.2 Hz, 3H), 3.01 – 2.89 (m, 2H), 1.73 (p, J = 6.7 Hz, 1H), 1.60 (dq, J = 11.6, 6.5, 5.6 Hz, 1H), 1.41 – 1.11 (m, 11H). ^{13}C NMR (101 MHz, DMSO) δ 162.34, 160.77, 155.88, 144.83, 129.97, 113.17, 112.83, 112.72, 101.57, 68.75, 51.26, 46.68, 41.81, 28.95, 28.91, 28.84, 26.48, 25.78, 23.61, 11.44, 9.07.

7-((8-(dipropylamino)octyl)oxy)-2H-chromen-2-one (7c)

^1H NMR (400 MHz, DMSO) δ 7.97 (d, J = 9.5 Hz, 1H), 7.60 (d, J = 8.6 Hz, 1H), 7.03 – 6.83 (m, 2H), 6.27 (d, J = 9.5 Hz, 1H), 4.05 (t, J = 6.5 Hz, 2H), 2.30 (dt, J = 14.2, 7.1 Hz, 5H), 1.71 (q, J = 6.9 Hz, 2H), 1.37 (dq, J = 14.5, 7.0 Hz, 6H), 1.32 – 1.18 (m, 5H), 0.81 (t, J = 7.3 Hz, 5H). ^{13}C NMR (101 MHz, DMSO) δ 162.36, 160.75, 155.90, 144.79, 129.91, 113.15, 112.82, 112.70, 101.56, 68.73, 56.00, 53.95, 29.35, 29.19, 28.86, 27.25, 27.09, 25.84, 20.36, 12.24.

7-((8-(dibutylamino)octyl)oxy)-2H-chromen-2-one (7d)

^1H NMR (400 MHz, DMSO) δ 7.96 (d, J = 9.5 Hz, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.00 – 6.82 (m, 2H), 6.25 (d, J = 9.5 Hz, 1H), 4.03 (t, J = 6.5 Hz, 2H), 2.28 (t, J = 7.0 Hz, 5H), 1.70 (p, J = 6.7 Hz, 2H), 1.38 (dd, J = 10.9, 4.9 Hz, 2H), 1.35 – 1.17 (m, 13H), 0.83 (t, J = 7.1 Hz, 5H). ^{13}C NMR (101 MHz, DMSO) δ 162.33, 144.71, 129.85, 113.05, 112.80, 112.68, 101.49, 68.69, 53.92, 53.63, 29.41, 29.37, 29.23, 28.90, 27.26, 27.13, 25.86, 20.49, 14.32.

7-((12-(dimethylamino)dodecyl)oxy)-2H-chromen-2-one (8a)

¹H NMR (400 MHz, DMSO) δ 7.65 (d, *J* = 15.5 Hz, 1H), 7.55 (d, *J* = 8.4 Hz, 1H), 6.98 (d, *J* = 15.4 Hz, 1H), 6.47 – 6.34 (m, 2H), 3.91 (t, *J* = 6.5 Hz, 3H), 3.10 (s, 3H), 2.90 (s, 3H), 2.74 – 2.67 (m, 2H), 2.54 (s, 4H), 1.67 (q, *J* = 6.9 Hz, 2H), 1.25 (s, 12H).
¹³C NMR (101 MHz, DMSO) δ 166.81, 161.23, 158.04, 136.96, 129.90, 115.42, 114.94, 106.66, 102.01, 67.84, 57.96, 43.64, 34.80, 29.43, 29.40, 29.33, 29.20, 29.11, 29.04, 26.66, 25.93, 25.29.

7-((12-(diethylamino)dodecyl)oxy)-2H-chromen-2-one (8b)

¹H NMR (400 MHz, DMSO) δ 7.99 (d, *J* = 9.5 Hz, 1H), 7.62 (d, *J* = 8.6 Hz, 1H), 7.00 – 6.86 (m, 2H), 6.28 (d, *J* = 9.5 Hz, 1H), 4.06 (t, *J* = 6.5 Hz, 2H), 3.01 (dq, *J* = 51.3, 11.5, 9.4 Hz, 5H), 1.72 (p, *J* = 6.7 Hz, 2H), 1.57 (t, *J* = 7.7 Hz, 2H), 1.43 – 1.11 (m, 19H).
¹³C NMR (101 MHz, DMSO) δ 162.33, 160.75, 144.81, 129.94, 113.16, 112.82, 112.70, 101.57, 68.74, 51.31, 46.69, 29.42, 29.40, 29.37, 29.30, 29.15, 29.01, 28.87, 26.53, 25.87.

7-((12-(dipropylamino)dodecyl)oxy)-2H-chromen-2-one (8c)

¹H NMR (400 MHz, DMSO) δ 7.99 (d, *J* = 9.5 Hz, 1H), 7.62 (d, *J* = 8.5 Hz, 1H), 7.05 – 6.82 (m, 2H), 6.28 (d, *J* = 9.5 Hz, 1H), 4.06 (t, *J* = 6.5 Hz, 2H), 3.34 (s, 3H), 2.97 (t, *J* = 8.5 Hz, 4H), 1.81 – 1.52 (m, 6H), 1.40 (t, *J* = 7.6 Hz, 2H), 1.35 – 1.17 (m, 11H), 0.89 (t, *J* = 7.3 Hz, 5H).
¹³C NMR (101 MHz, DMSO) δ 162.33, 160.75, 155.87, 144.81, 129.94, 113.15, 112.82, 112.70, 101.57, 68.74, 53.95, 52.51, 29.43, 29.40, 29.37, 29.30, 29.16, 28.99, 28.88, 26.51, 25.87, 11.33.

7-((12-(dibutylamino)dodecyl)oxy)-2H-chromen-2-one (8d)

¹H NMR (400 MHz, DMSO) δ 7.97 (d, *J* = 9.5 Hz, 1H), 7.60 (d, *J* = 8.6 Hz, 1H), 7.02 – 6.83 (m, 2H), 6.27 (d, *J* = 9.5 Hz, 1H), 4.04 (t, *J* = 6.5 Hz, 2H), 2.38 (s, 4H), 1.71 (p, *J* = 6.7 Hz, 2H), 1.44 – 1.15 (m, 19H), 0.85 (t, *J* = 7.2 Hz, 5H).
¹³C NMR (101 MHz, DMSO) δ 162.33, 155.88, 144.76, 129.89, 113.11, 112.81, 112.68, 101.54, 68.71, 55.35, 29.44, 29.42, 29.40, 29.30, 29.16, 28.89, 27.14, 25.87, 20.40, 14.30.

4-hydroxy-2H-chromen-2-one (10)

¹H NMR (400 MHz, DMSO-d6) δ = 12.49 (s, 1H), 7.81 (d, *J* = 7.8 Hz, 1H), 7.62 (t, *J* = 8.4 Hz, 1H), 7.41 – 7.21 (m, 2H), 5.60 (s, 1H).

4-(4-bromobutoxy)-2H-chromen-2-one (11)

¹H NMR (400 MHz, CDCl₃) δ = 7.82 – 7.80 (d, *J* = 8 Hz, 1H), 7.58 – 7.55 (t, 1H), 7.32 – 7.26 (m, 2H), 5.68 (s, 1H), 4.20 – 4.17 (t, *J* = 6 Hz, 2H), 3.54 – 3.51 (t, *J* = 6 Hz, 2H), 2.12 – 2.11 (m, 4H). ¹³C NMR (100 MHz, DMSO) δ = 165.42, 162.76, 153.22, 132.35, 123.84, 122.84, 116.69, 115.54, 90.46, 68.35, 32.78, 29.17, 27.10. TOF-MS, m/z: [M+H⁺] calculated for C₁₃H₁₃BrO₃, 296.0048, found: 297.0098.

4-((8-bromoocetyl)oxy)-2H-chromen-2-one (12)

¹H NMR (400 MHz, CDCl₃) δ = 7.82 – 7.80 (d, *J* = 8 Hz, 1H), 7.58 – 7.55 (t, 1H), 7.32 – 7.26 (m, 2H), 5.68 (s, 1H), 4.20 – 4.17 (t, *J* = 6 Hz, 2H), 3.54 – 3.51 (t, *J* = 6 Hz, 2H), 2.12 – 2.11 (m, 4H). ¹³C NMR (100 MHz, DMSO) δ = 165.42, 162.76, 153.22, 132.35, 123.84, 122.84, 116.69, 115.54, 90.46, 68.35, 32.78, 29.17, 27.10. TOF-MS, m/z: [M+H⁺] calculated for C₁₃H₁₃BrO₃, 296.0048, found: 297.0098.

4-((12-bromododecyl)oxy)-2H-chromen-2-one (13)

¹H NMR (400 MHz, CDCl₃) δ = 7.84 – 7.82 (d, *J* = 8 Hz, 1H), 7.57 – 7.53 (t, 1H), 7.33 – 7.26 (m, 2H), 5.67 (s, 1H), 4.15 – 4.12 (t, *J* = 6 Hz, 2H), 3.43 – 3.40 (t, *J* = 6 Hz, 2H), 1.93 – 1.82 (m, 4H), 1.55 – 1.30 (m, 16H). ¹³C NMR (100 MHz, DMSO) δ = 165.68, 162.99, 153.31, 132.26, 123.77, 122.97, 116.72, 115.80, 90.33, 69.39, 34.02, 32.77, 29.44, 29.42, 29.37, 29.18, 28.71, 28.43, 28.12, 25.90. TOF-MS, m/z: [M+H⁺] calculated for C₂₁H₂₉BrO₃, 408.1300, found: 409.1328.

4-(4-(dimethylamino)butoxy)-2H-chromen-2-one (14a)

¹H NMR (400 MHz, CDCl₃) δ 7.81 (d, *J* = 7.8 Hz, 1H), 7.54 (t, *J* = 7.9 Hz, 1H), 7.34 – 7.26 (m, 2H), 5.69 (s, 1H), 4.20 (t, *J* = 5.8 Hz, 2H), 3.47 (d, *J* = 14.2 Hz, 1H), 3.25 – 3.09 (m, 2H), 2.85 (d, *J* = 2.6 Hz, 6H), 2.11 (dt, *J* = 44.1, 7.9 Hz, 4H). ¹³C NMR (101

MHz, CDCl₃) δ 165.37, 162.83, 153.25, 132.57, 124.12, 122.98, 116.78, 115.42, 90.74, 68.13, 57.62, 43.19, 43.16, 25.88, 21.47.

4-(4-(diethylamino)butoxy)-2H-chromen-2-one (14b)

¹H NMR (400 MHz, CDCl₃) δ 7.74 (dd, *J* = 8.2, 1.6 Hz, 1H), 7.46 (ddd, *J* = 8.7, 7.3, 1.6 Hz, 1H), 7.24 – 7.16 (m, 2H), 5.63 (s, 1H), 4.15 (t, *J* = 6.0 Hz, 2H), 3.44 (q, *J* = 7.2 Hz, 1H), 3.13 (p, *J* = 7.3 Hz, 5H), 2.14 – 1.89 (m, 4H), 1.37 (dt, *J* = 18.5, 7.3 Hz, 7H). ¹³C NMR (101 MHz, CDCl₃) δ 165.50, 162.92, 153.11, 132.46, 124.08, 123.06, 123.02, 116.57, 115.42, 90.55, 68.45, 51.52, 46.85, 26.01, 20.81, 8.88.

4-(4-(dipropylamino)butoxy)-2H-chromen-2-one (14c)

¹H NMR (400 MHz, CDCl₃) δ 7.77 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.48 (ddd, *J* = 8.6, 7.2, 1.6 Hz, 1H), 7.27 – 7.17 (m, 2H), 5.61 (s, 1H), 4.10 (t, *J* = 6.4 Hz, 2H), 2.49 – 2.39 (m, 2H), 2.38 – 2.28 (m, 4H), 1.88 (dq, *J* = 8.5, 6.5 Hz, 2H), 1.66 – 1.53 (m, 2H), 1.46 – 1.33 (m, 4H), 0.82 (t, *J* = 7.4 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 165.65, 162.92, 132.23, 123.75, 122.97, 116.63, 90.30, 69.34, 56.16, 53.64, 26.51, 23.74, 20.18, 11.90.

4-(4-(dibutylamino)butoxy)-2H-chromen-2-one (14d)

¹H NMR (400 MHz, CDCl₃) δ 7.83 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.55 (ddd, *J* = 8.6, 7.1, 1.6 Hz, 1H), 7.38 – 7.24 (m, 2H), 5.70 (s, 1H), 4.19 (t, *J* = 5.8 Hz, 2H), 3.46 (d, *J* = 1.6 Hz, 2H), 2.99 – 2.93 (m, 2H), 2.87 (d, *J* = 5.4 Hz, 2H), 2.77 (t, *J* = 8.1 Hz, 3H), 2.02 – 1.85 (m, 4H), 1.62 (ddd, *J* = 12.3, 9.8, 6.3 Hz, 3H), 1.37 (dq, *J* = 14.9, 7.5 Hz, 4H), 0.94 (dd, *J* = 8.0, 6.8 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 165.58, 163.00, 153.24, 132.46, 123.99, 123.01, 116.71, 115.58, 90.50, 68.76, 53.04, 52.99, 47.70, 27.83, 26.26, 20.39, 20.09, 13.78, 13.49.

4-((8-(dimethylamino)octyl)oxy)-2H-chromen-2-one (15a)

¹H NMR (400 MHz, CDCl₃) δ 7.79 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.52 (ddd, *J* = 8.6, 7.1, 1.6 Hz, 1H), 7.35 – 7.17 (m, 2H), 5.63 (s, 1H), 4.10 (t, *J* = 6.4 Hz, 2H), 2.71 – 2.57

(m, 2H), 1.87 (m, $J = 6.7$ Hz, 2H), 1.67 (m, $J = 7.3$ Hz, 2H), 1.53 – 1.42 (m, 2H), 1.36 (h, $J = 5.9, 5.0$ Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 165.70, 153.32, 132.32, 123.85, 123.01, 116.74, 90.35, 69.32, 58.88, 44.07, 29.13, 29.03, 28.41, 26.93, 25.84.

4-((8-(diethylamino)octyl)oxy)-2H-chromen-2-one (15b)

^1H NMR (400 MHz, CDCl_3) δ 7.80 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.53 (ddd, $J = 8.6, 7.2, 1.6$ Hz, 1H), 7.35 – 7.20 (m, 2H), 5.64 (s, 1H), 4.11 (t, $J = 6.4$ Hz, 2H), 3.13 (q, $J = 7.3$ Hz, 4H), 3.03 – 2.92 (m, 2H), 1.86 (dp, $J = 14.8, 6.8$ Hz, 4H), 1.57 – 1.32 (m, 14H). ^{13}C NMR (101 MHz, CDCl_3) δ 165.69, 153.30, 132.35, 123.89, 123.01, 116.71, 115.76, 90.35, 69.25, 51.41, 46.62, 28.95, 28.88, 28.36, 26.78, 25.78, 23.28.

4-((8-(dipropylamino)octyl)oxy)-2H-chromen-2-one (15c)

^1H NMR (400 MHz, CDCl_3) δ 7.79 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.51 (ddd, $J = 8.7, 7.3, 1.6$ Hz, 1H), 7.37 – 7.18 (m, 2H), 5.63 (s, 1H), 4.09 (t, $J = 6.4$ Hz, 2H), 2.46 – 2.27 (m, 7H), 1.98 – 1.80 (m, 2H), 1.60 – 1.21 (m, 17H), 0.84 (t, $J = 7.4$ Hz, 7H). ^{13}C NMR (101 MHz, CDCl_3) δ 165.67, 132.24, 123.77, 122.97, 116.69, 115.80, 90.31, 69.39, 56.22, 54.19, 29.43, 29.21, 28.44, 27.49, 27.01, 25.89, 20.12, 20.10, 11.97.

4-((8-(dibutylamino)octyl)oxy)-2H-chromen-2-one (15d)

^1H NMR (400 MHz, CDCl_3) δ 7.77 (dd, $J = 7.9, 1.6$ Hz, 1H), 7.49 (ddd, $J = 8.7, 7.3, 1.6$ Hz, 1H), 7.31 – 7.16 (m, 2H), 5.62 (s, 1H), 4.08 (t, $J = 6.4$ Hz, 2H), 2.46 – 2.29 (m, 5H), 1.95 – 1.79 (m, 2H), 1.54 – 1.17 (m, 15H), 0.87 (t, $J = 7.3$ Hz, 5H). ^{13}C NMR (101 MHz, CDCl_3) δ 165.66, 162.93, 132.23, 123.76, 122.97, 116.66, 90.29, 69.38, 54.11, 53.83, 29.42, 29.20, 29.04, 28.43, 27.48, 26.92, 25.88, 20.74, 14.06.

4-((12-(dimethylamino)dodecyl)oxy)-2H-chromen-2-one (16a)

^1H NMR (400 MHz, DMSO) δ 7.65 (d, $J = 15.5$ Hz, 1H), 7.55 (d, $J = 8.4$ Hz, 1H), 6.98 (d, $J = 15.4$ Hz, 1H), 6.42 (t, $J = 1.9$ Hz, 2H), 3.91 (t, $J = 6.5$ Hz, 3H), 3.10 (s, 3H), 2.90 (s, 3H), 2.71 (s, 2H), 2.54 (s, 4H), 1.68 (m, $J = 6.7$ Hz, 2H), 1.26 (d, $J = 8.5$ Hz, 12H). ^{13}C NMR (101 MHz, DMSO) δ 166.81, 161.23, 158.04, 136.96, 129.90,

115.42, 114.94, 106.66, 102.01, 67.84, 57.96, 43.64, 34.80, 29.43, 29.40, 29.33, 29.20, 29.11, 29.04, 26.66, 25.93, 25.29.

4-((12-(diethylamino)dodecyl)oxy)-2H-chromen-2-one (16b**)**



¹H NMR (400 MHz, DMSO) δ 7.99 (d, *J* = 9.5 Hz, 1H), 7.62 (d, *J* = 8.6 Hz, 1H), 7.00 – 6.86 (m, 2H), 6.28 (d, *J* = 9.5 Hz, 1H), 4.06 (t, *J* = 6.5 Hz, 2H), 3.01 (dq, *J* = 51.3, 11.5, 9.4 Hz, 5H), 1.71 (q, *J* = 6.9 Hz, 2H), 1.57 (t, *J* = 7.7 Hz, 2H), 1.43 – 1.11 (m, 19H). ¹³C NMR (101 MHz, DMSO) δ 162.33, 160.75, 144.81, 129.94, 113.16, 112.82, 112.70, 101.57, 68.74, 51.31, 46.69, 29.42, 29.40, 29.37, 29.30, 29.15, 29.01, 28.87, 26.53, 25.87.

4-((12-(dipropylamino)dodecyl)oxy)-2H-chromen-2-one (16c**)**

¹H NMR (400 MHz, DMSO) δ 7.99 (d, *J* = 9.5 Hz, 1H), 7.62 (d, *J* = 8.5 Hz, 1H), 7.05 – 6.82 (m, 2H), 6.28 (d, *J* = 9.5 Hz, 1H), 4.06 (t, *J* = 6.5 Hz, 2H), 3.34 (s, 3H), 2.96 (t, *J* = 8.6 Hz, 4H), 1.81 – 1.52 (m, 6H), 1.45 – 1.19 (m, 13H), 0.89 (t, *J* = 7.3 Hz, 5H). ¹³C NMR (101 MHz, DMSO) δ 162.33, 160.75, 155.87, 144.81, 129.94, 113.15, 112.82, 112.70, 101.57, 68.74, 53.95, 52.51, 29.43, 29.40, 29.37, 29.30, 29.16, 28.99, 28.88, 26.51, 25.87, 11.33.

4-((12-(dibutylamino)dodecyl)oxy)-2H-chromen-2-one (16d**)**

¹H NMR (400 MHz, DMSO) δ 7.97 (d, *J* = 9.5 Hz, 1H), 7.60 (d, *J* = 8.6 Hz, 1H), 7.02 – 6.83 (m, 2H), 6.27 (d, *J* = 9.5 Hz, 1H), 4.04 (t, *J* = 6.5 Hz, 2H), 2.38 (s, 4H), 1.71 (m, *J* = 6.7 Hz, 2H), 1.52 – 1.16 (m, 20H), 0.85 (t, *J* = 7.2 Hz, 5H). ¹³C NMR (101 MHz, DMSO) δ 162.33, 160.72, 155.88, 144.76, 129.89, 113.11, 112.81, 112.68, 101.54, 68.71, 55.35, 29.44, 29.42, 29.40, 29.30, 29.16, 28.89, 25.87, 20.40, 14.30.






Fig.S3 ^{13}C NMR of **3** (100 MHz, DMSO)




Fig.S4 ^1H NMR of **4** (400 MHz, DMSO)




Fig.S5 ¹³C NMR of 4 (100 MHz, DMSO)




Fig.S6 ¹H NMR of 5 (400 MHz, CDCl₃)




Fig.S7 ^{13}C NMR of **5** (100 MHz, CDCl_3)




Fig.S8 1H NMR of **6a** (400 MHz, DMSO)




Fig.S9 ^{13}C NMR of **6a** (100 MHz, DMSO)




Fig.S10 ^1H NMR of **6b** (400 MHz, DMSO)




Fig.S11 ^{13}C NMR of **6b** (100 MHz, DMSO)




Fig.S12 1H NMR of **6c** (400 MHz, DMSO)




Fig.S13 ^{13}C NMR of **6c** (400 MHz, DMSO)




Fig.S14 ^1H NMR of **6d** (400 MHz, CDCl_3)




Fig.S15 ^{13}C NMR of **6d** (400 MHz, CDCl_3)




Fig.S16 ^1H NMR of **7a** (400 MHz, DMSO)




Fig.S17 ^{13}C NMR of **7a** (400 MHz, DMSO)




Fig.S18 ^1H NMR of **7b** (400 MHz, DMSO)




Fig.S19 ¹³C NMR of **7b** (400 MHz, DMSO)




Fig.S20 ¹H NMR of **7c** (400 MHz, DMSO)




Fig.S21 ^{13}C NMR of **7c** (400 MHz, DMSO)




Fig.S22 ^1H NMR of **7d** (400 MHz, DMSO)




Fig.S23 ^{13}C NMR of **7d** (400 MHz, DMSO)




Fig.S24 ^1H NMR of **8a** (400 MHz, DMSO)




Fig.S25 ^{13}C NMR of **8a** (400 MHz, DMSO)




Fig.S26 ^1H NMR of **8b** (400 MHz, DMSO)




Fig.S27 ^{13}C NMR of **8b** (400 MHz, DMSO)




Fig.S28 1H NMR of **8c** (400 MHz, DMSO)




Fig.S29 ^{13}C NMR of **8c** (400 MHz, DMSO)




Fig.S30 ^1H NMR of **8d** (400 MHz, DMSO)




Fig.S31 ^{13}C NMR of **8d** (400 MHz, DMSO)




Fig.S32 ^1H NMR of **10** (400 MHz, DMSO)




Fig.S33 ^1H NMR of **11** (400 MHz, CDCl_3)




Fig.S34 ^{13}C NMR of **11** (100 MHz, CDCl_3)




Fig.S35 ^1H NMR of **12** (400 MHz, CDCl_3)




Fig.S36 ^{13}C NMR of **12** (100 MHz, CDCl_3)




Fig.S37 ^1H NMR of **13** (400 MHz, CDCl_3)




Fig.S38 ^{13}C NMR of **13** (100 MHz, CDCl_3)




Fig.S39 ¹H NMR of 14a (400 MHz, CDCl₃)




Fig.S40 ¹³C NMR of 14a (100 MHz, CDCl₃)




Fig.S41 ^1H NMR of 14b (400 MHz, CDCl_3)




Fig.S42 ^{13}C NMR of 14b (100 MHz, CDCl_3)




Fig.S43 ^1H NMR of **14c** (400 MHz, CDCl_3)




Fig.S44 ^{13}C NMR of **14c** (100 MHz, CDCl_3)




Fig.S45 ^1H NMR of **14d** (400 MHz, CDCl_3)




Fig.S46 ^{13}C NMR of **14d** (100 MHz, CDCl_3)




Fig.S47 ^1H NMR of **15a** (400 MHz, CDCl_3)




Fig.S48 ^{13}C NMR of **15a** (100 MHz, CDCl_3)




Fig.S49 ^1H NMR of **15b** (400 MHz, CDCl_3)




Fig.S50 ^{13}C NMR of **15b** (100 MHz, CDCl_3)




Fig.S51 ^1H NMR of **15c** (400 MHz, CDCl_3)




Fig.S52 ^{13}C NMR of **15c** (400 MHz, CDCl_3)




Fig.S53 ^1H NMR of **15d** (400 MHz, CDCl_3)




Fig.S54 ^{13}C NMR of **15d** (400 MHz, CDCl_3)




Fig.S55 1H NMR of **16a** (400 MHz, DMSO)




Fig.S56 ^{13}C NMR of **16a** (400 MHz, DMSO)




Fig.S57 ^1H NMR of **16b** (400 MHz, DMSO)




Fig.S58 ^{13}C NMR of **16b** (400 MHz, DMSO)




Fig.S59 1H NMR of **16c** (400 MHz, DMSO)




Fig.S60 ^{13}C NMR of **16c** (400 MHz, DMSO)




Fig.S61 1H NMR of **16d** (400 MHz, DMSO)




Fig.S62 ^{13}C NMR of **16d** (400 MHz, DMSO)